A selective ACAT-1 inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice

Atherosclerosis

Volumn 213, Issue 1, 2010, Pages 85-91

  Yoshinaka, Yasunobu ^a   Shibata, Haruki ^a   Kobayashi, Hideyuki ^a   Kuriyama, Hiroki ^a   Shibuya, Kimiyuki ^a   Tanabe, Sohei ^a   Watanabe, Takuya ^b   Miyazaki, Akira ^b  

^a KOWA COMPANY LTD   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ACAT inhibitor; Collagen; Macrophage; Plaque phenotype; Smooth muscle cell

Indexed keywords

CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; COLLAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; K 604; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PACTIMIBE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; FOAM CELL; GENE EXPRESSION; HISTOLOGY; HYPERCHOLESTEROLEMIA; IMMUNOBLOTTING; KNOCKOUT MOUSE; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE;

ACETYL-COA C-ACETYLTRANSFERASE; ANIMALS; AORTA; APOLIPOPROTEINS E; BENZIMIDAZOLES; CELLS, CULTURED; COLLAGEN; HUMANS; LIPOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE;

EID: 77958459353     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.08.048     Document Type: Article

References (23)

1. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008, 263:517-527.
2. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995, 92:657-671.
3. Braunwald E. Shattuck lecture: cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997, 337:1360-1369.
4. Chang T.Y., Li B.L., Chang C.C., et al. Acyl-coenzyme A:cholesterol acyltransferase. Am J Physiol Endocrinol Metab 2009, 297:E1-E9.
5. Miyazaki A., Sakashita N., Lee O., et al. Expression of ACAT-1protein in human atherosclerotic lesions and cultured human monocyte-macrophages. Arterioscler Thromb Vasc Biol 1998, 18:1568-1574.
6. Miyazaki A., Kanome T., Watanabe T. Inhibitors of acyl-coenzyme A:cholesterol acyltransferase. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5:463-469.
7. Kusunoki J., Hansoty D.K., Aragane K., et al. Acyl-coenzyme A (CoA):cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001, 103:2604-2609.
8. Terasaka N., Miyazaki A., Kasanuki N., et al. ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice. Atherosclerosis 2007, 190:239-247.
9. Kitayama K., Koga T., Maeda N., et al. Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits. Eur J Pharmacol 2006, 539:81-88.
10. Fazio S., Major A.S., Swift L.L., et al. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest 2001, 107:163-171.
11. Ikenoya M., Yoshinaka Y., Kobayashi H., et al. A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis 2007, 191:290-297.
12. Garber D.W., Kulkarni K.R., Anantharamaiah G.M. A senitive method for lipoprotein profile analysis of individual plasma samples. J Lipid Res 2000, 41:1020-1026.
13. van der Wal A.C., Becker A.E., van der Loos C.M., et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44.
14. + T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol 1996, 149:359-366.
15. Kavitha O., Thampan R.V. Factors influencing collagen biosynthesis. J Cell Biochem 2008, 104:1150-1160.
16. Bobik A. Transforming growth factor-βs and vascular diseases. Arterioscler Thromb Vasc Biol 2006, 26:1712-1720.
17. Dove D.E., Su Y.R., Zhang W., et al. ACAT1 deficiency disrupts cholesterol efflux and alters morphology in macrophages. Arterioscler Thromb Vasc Biol 2005, 25:128-134.
18. Yokoyama T., Yoshinaka Y., Kobayashi H., et al. Selective inhibition of ACAT-1 accelerates plaque stabilization in atherosclerotic lesion without affecting plasma cholesterol. Circulation 2004, 110. III-124.
19. Saxena U., Ferguson E., Newton R.S. Acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitors modulate monocyte adhesion to aortic endothelial cells. Atherosclerosis 1995, 112:7-17.
20. Delsing D.J., Offerman E.H., van Duyvenvoorde W., et al. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in apoE*3-Leiden mice. Circulation 2001, 103:1778-1786.
21. Tardif J.C., Gregoire J., L'Allier P.L., et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004, 110:3372-3377.
22. Nissen S.E., Tuzcu E.M., Brewer H.B., et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006, 354:1253-1263.
23. Meuwese M.C., de Groot E., Duivenvoorden R., et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia. JAMA 2009, 301:1131-1139.